Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.53 |
| ▸ | TLR1 | Q15399 | 6/20 | 0.53 |
| ▸ | NAMPT | P43490 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737768 | 0.92 | NAMPT (0.62) | TLR2TLR1NAMPTNPC1L1SIGMAR1 | |
| SCHEMBL13738400 | 0.83 | NAMPT (0.59) | TLR2TLR1NAMPTKDM4EPKM | |
| SCHEMBL3285436 | 0.81 | PKM (0.61) | NAMPTKDM4EPKMACACBACACA | |
| SCHEMBL5969167 | 0.80 | MEN1 (0.43) | NAMPTSIGMAR1CNR2 | |
| SCHEMBL8298895 | 0.78 | NAMPT (0.54) | TLR2TLR1NAMPTNPC1L1RBP4 | |
| SCHEMBL5968986 | 0.77 | SYK (0.47) | NAMPTSIGMAR1 | |
| SCHEMBL24392263 | 0.77 | NAMPT (0.51) | NAMPTKDM4EPKM | |
| SCHEMBL4703208 | 0.77 | CHRM4 (0.56) | KDM4EPKMACACBACACA | |
| SCHEMBL9144556 | 0.76 | HTT (0.51) | KDM4EPKMSIGMAR1 | |
| SCHEMBL9270099 | 0.75 | TLR2 (0.48) | TLR2TLR1NAMPTRBP4CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | TLR2 3145/4885TLR1 2589/4885NAMPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.